beta

ADAP

Adaptimmune Therapeutics Plc

Adap

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Market Cap: 130 Million

Primary Exchange: NASDAQ

Website: http://adaptimmune.com

Shares Outstanding: 105 Million

Float: 87.8 Million

Dividend: (%)

Beta: 1.70423921215491

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Animal testing

Longest drawdown: 1149 trading days

From: 2015-06-16 To: 2019-12-12

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud